Join to View Full Profile
75 Francis StBoston, MA 02115
Phone+1 617-732-5500
Dr. Dagogo-Jack is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2017- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2011 - 2014
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2011
Certifications & Licensure
NH State Medical License 2021 - 2027
MA State Medical License 2015 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Publications & Presentations
PubMed
- A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non...Melissa L Johnson, Egbert F Smit, Enriqueta Felip, Suresh S Ramalingam, Myung-Ju Ahn
Future Oncology. 2026-04-01 - Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer.Jaime L Schneider, Alona Muzikansky, Elizabeth Krueger, Justin F Gainor, Jessica J Lin
Lung Cancer. 2026-03-01 - Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer.Takashi Sakai, Zofia Piotrowska, Charlotte I Wang, Beow Y Yeap, Rebecca S Heist
Biorxiv. 2026-01-23
Lectures
- Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors.2019 ASCO Annual Meeting - 6/1/2019
- Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Lung Cancer Research Foundation Creates Scientific Executive CommitteeJuly 11th, 2022- Join VA and the White House Today for a Cancer Cabinet Community ConversationMay 4th, 2022
- In Expected Decision, FDA Rejects Lilly's Sintilimab in NSCLCMarch 24th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
